Survey
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
ALD: Adrenoleukodystrophy Adreno = Leuko = white (as in white matter) Dys = abnormal; ill Trophy = growth Demyelinating diseases Normal vs. demyelinated axons ALD is an X-linked disease 1/20,000 males affected The ALD phenotype is variable, even within families. The same mutations in ALD will not always produce similar phenotypes. 1. 48% - Childhood Cerebral 2. 26% - Adrenomyeloneuropathy 3. 10% - Addison Disease Only 4. 8% - Pre-/Asymptomatic 5. 5% - Adolescent Cerebral ALD 6. 3% - Adult Cerebral ALD Female ALD carrier 2. Female Phenotypes (2) • 85-95% - Asymptomatic • 10-15% - Adrenomyeloneuropathy - late onset, less severe Lipid Biology • Hot topic • Saturated vs. unsaturated fatty acids • VLCSFAs: hexacosenoic acid C26:0 and tetracosenoic acid C24:0 • One hypothesis: VLCSFAs insert into and solubilize myelin sheath (not true for VLCFAs) Fats How does the body normally oxidize fatty acids? VLCFA breakdown in peroxisomes ( oxidation) Through series of chemical reactions, fatty acids are shortened by removing two carbons at a time. Pathophysiology of X-ALD • Demyelination diseases (acquired vs. genetic) • Deficiency of long-chain fatty acyl CoA synthase, a perioxisomal enxyme needed for the degradation of very long chain fatty acids (VLCFA). • Reason: Transport across peroxisome membrane does not work – defective peroxisomal membrane transporter specific for uptake of long-chain fatty acyl CoA synthase from the cytosol. Normal peroxisome (normal oxidation of VLCFA's) ALD peroxisome (no oxidation of VLCFA's) Treatment??? • Reduce intake of VLCSFAs VLCSFA ????? • Previous reference (1979): Intake of unsaturated short chain oleic acid (C18) reduction of VLCSFA • But why does it work??? Competitive inhibition!! http://www.myelin.org/aboutoil.htm Sink model animation More potent competitive inhibitor • After 3 month VLCSFAs are still too high • Stronger CI needed • Enter: Erucic acid (C22) – unsaturated • VLCSFA down to normal levels • “Lorenzo’s oil”: 4 parts oleic acid + 1 part erucic acid One Problem: Lorenzo’s Oil may not work • Preventive vs. therapeutic effects • New therapies: – gene therapy – Stem cells The End